Paolo Pucci
Director/Board Member at WEST PHARMACEUTICAL SERVICES, INC.
Net worth: 4 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philip Astley-Sparke | M | 52 | 9 years | |
| Bill Lundberg | M | 60 | 5 years | |
| Robert Coffin | M | 59 | 9 years | |
| Kapil Dhingra | M | 64 | 12 years | |
| Peter Silverman | M | 46 | 7 years | |
| Sushil Patel | M | 53 | 3 years | |
| Bernard Birkett | M | 55 | 6 years | |
| Eric Green | M | 55 | 9 years | |
| Gregory Perry | M | 63 | 8 years | |
| Mark Iwicki | M | 57 | 9 years | |
| Sushant Kumar | M | - |
Tarus Therapeutics, Inc.
 Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
| Dieter Weinand | M | 63 | 6 years | |
| Anand Mehra | M | 48 | 9 years | |
| Christy Oliger | F | 54 | 3 years | |
| Robert Glassman | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 years |
| Andrew Schwendenman | M | 48 | 4 years | |
| Silji Abraham | M | 52 | 6 years | |
| Kimberly MacKay | F | 58 | 4 years | |
| Victor Sandor | M | 57 | 5 years | |
| Len Kanavy | M | 62 | 6 years | |
| Cindy Reiss-Clark | F | 50 | - | |
| Sherri L. Spear | F | - | - | |
| Andrew Muratore | M | - | 3 years | |
| Deborah Baron | F | 55 | 3 years | |
| Deborah Keller | F | 61 | 7 years | |
| Molly Joseph | F | 50 | 3 years | |
| David Epstein | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 years |
| Colin Love | M | 66 | 9 years | |
| Douglas Michels | M | 66 | 13 years | |
| William Feehery | M | 54 | 12 years | |
| Robert Friel | M | 68 | 4 years | |
| Thomas Hofmann | M | 72 | 17 years | |
| Myla Lai-Goldman | M | 66 | 10 years | |
| Joseph Slattery | M | 59 | 7 years | |
| Mark Buthman | M | 63 | 13 years | |
| Veleka Peeples-Dyer | F | 52 | 1 years | |
| Hyam Levitsky | M | 66 | 6 years | |
| Peter Molloy | M | 52 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
| Stephen Lockhart | M | 65 | 2 years | |
| John de Kruif | M | 60 | 17 years | |
| Christopher Sarchi | M | 56 | 1 years | |
| Konstantinos Xynos | M | 58 | 2 years | |
| Michele Polinsky | M | - | - | |
| Robert Segura | M | - | 3 years | |
| Donald A. McMillan | M | 65 | 27 years | |
| Ernesto Wasserman | M | - | 8 years | |
| Shannon Campbell | F | - | 2 years | |
| Chris Ryan | M | - | - | |
| Kathleen Farren | F | - | - | |
| Alexander Berthold Hendrik Bakker | M | 57 | 14 years | |
| Paul Achleitner | M | 67 | 22 years | |
| Andrew Joe | M | 58 | 4 years | |
| Harry Shuman | M | - | - | |
| Maxine Gowen | M | 66 | 3 years | |
| Mark S. Cohen | M | 56 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 years |
| Emily Hill | F | 44 | 1 years | |
| Arleen Goldenberg | F | - | - | |
| Chad Winters | M | 45 | 5 years | |
| Quintin Lai | M | 57 | 8 years | |
| Annette Favorite | F | 59 | 9 years | |
| C. Nicholson | M | 68 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 years |
| Liu Hui | M | 51 | 9 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew Ashe | M | 57 | 13 years | |
| George Migausky | M | 69 | 8 years | |
| Jean Franchi | F | 57 | 4 years | |
| Gustav Christensen | M | 76 | 9 years | |
| Jan Skvarka | M | 57 | 2 years | |
| Robert L. Kirkman | M | 75 | 8 years | |
| Robert A. Uger | M | 53 | 8 years | |
| David J. McLachlan | M | 86 | 17 years | |
| Henry E. Blair | M | 80 | 27 years | |
| James Parsons | M | 58 | 10 years | |
| Ivana Magovcevic-Liebisch | M | 55 | 12 years | |
| Patrick Zenner | M | 77 | 20 years | |
| John Weiland | M | 68 | 12 years | |
| Frank Morich | M | 69 | 20 years | |
| Thomas Hoffmann | M | 53 | 5 years | |
| Ulrich Hauck | M | 60 | 12 years | |
| Penka Petrova | M | 56 | 8 years | |
| Joseph Saluri | M | 57 | 7 years | |
| Willy Beumann | M | 68 | - | |
| Johannes M. Dietsch | M | 62 | 16 years | |
| Bernd Metzner | M | 53 | 4 years | |
| Mark Throsby | M | 57 | 12 years | |
| Paul Walker | M | 49 | 1 years | |
| Jason Rhodes | M | 54 | 7 years | |
| Hugo Slootweg | M | 53 | 8 years | |
| Tanya Lewis | F | 53 | 4 years | |
| William Federici | M | 64 | 15 years | |
| Otello Stampacchia | M | 55 | 7 years | |
| Klaus Sturany | M | 77 | - | |
| Paula Johnson | M | 64 | 16 years | |
| Mary Gray | M | 71 | 12 years | |
| Klaus-Christian Kleinfeld | M | 65 | 9 years | |
| Paul Edick | M | 67 | 7 years | |
| Helmut Gunter Wilhelm Panke | M | 77 | - | |
| Michael A. Anderson | M | 68 | 24 years | |
| David Montecalvo | M | 58 | 6 years | |
| Thomas Lenox Kempner | M | 96 | 21 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 36 | 36.36% |
| Switzerland | 27 | 27.27% |
| Netherlands | 18 | 18.18% |
| Germany | 10 | 10.10% |
| Canada | 8 | 8.08% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paolo Pucci
- Personal Network